Vigil Neuroscience Inc (VIGL) AI Stock Analysis

• Market Cap: $84.01M
• Dividend Yield: N/A
• Average Volume (3M): 243.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: N/A
• EPS Growth: 3.01%
• Country: US
• Employees: 69
• Sector: Healthcare
• Sector Strength: 66
• Industry: Biotechnology
• EPS (TTM): -2.07
• Shares Outstanding: 46,671,535
• 10 Day Avg. Volume: 162,366
• 30 Day Avg. Volume: 243,290
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• Price to Cash Flow (P/CF): -1.20
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $15.00
• Price Target Upside: 733.33% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

Vigil Neuroscience Inc's overall score is primarily affected by its poor financial performance, characterized by zero revenue and ongoing losses, which heavily weigh down its potential. Technical indicators suggest bearish momentum, and valuation metrics indicate high risk. However, the positive Phase 1 trial results provide a glimmer of hope, suggesting potential future growth if subsequent trials are successful.

Positive Factors

Drug Development

Vigil plans to pursue an accelerated approval pathway after the FDA said it was open to the approach following a prior Type C meeting.

Partnership Opportunities

The likelihood that Vigil Neuroscience strikes a large Alzheimer's disease-focused partnership deal for VG-3927 before the Phase 2 study start is quite high.

Regulatory Approvals

FDA had shown interest for a potential accelerated approval pathway for iluzanebart.

Negative Factors

Financial Performance

Revisiting operational expense assumptions beyond 2025 reduces the price target to $14 from $17.

Market Sentiment

There is likely near-term negative sentiment on the TREM2 target, possibly affecting VIGL shares.

Vigil Neuroscience Inc Business Overview & Revenue Model

Company Description

Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Vigil Neuroscience Inc generates revenue primarily through strategic partnerships, collaborations, and potential licensing agreements with other pharmaceutical and biotechnology companies. These partnerships often involve milestone payments, research and development funding, and royalties on future product sales. The company may also secure grants and funding from governmental or non-governmental organizations to support its research initiatives. Additionally, as its products progress through clinical trials and reach commercialization, Vigil Neuroscience may generate revenue from the direct sales of its therapeutic products. However, as of the latest available data, the company is likely still in the pre-revenue stage, focusing heavily on research and development activities.

Vigil Neuroscience Inc Financial Statement Overview

Summary

Vigil Neuroscience Inc is facing significant financial challenges, with zero revenue and persistent losses. The balance sheet shows some improvement in equity, but overall financial health remains weak due to negative cash flows and high accumulated losses.

Income Statement

Vigil Neuroscience Inc has consistently reported zero revenue over the past years, resulting in negative EBIT and net income. The lack of revenue and high losses indicate a challenging financial position. The company's gross and net profit margins are non-existent, highlighting the absence of income generation.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio, but this is complicated by the negative stockholders' equity in earlier years, which reflects financial instability. The equity ratio is improving, with positive equity in recent years, but overall financial health remains weak. The availability of cash and short-term investments provides some liquidity, but the high accumulated losses are concerning.

Cash Flow

Vigil Neuroscience Inc exhibits negative free cash flow, indicating that the company is not generating enough cash to cover its operations and capital expenditures. The operating cash flow to net income ratio is consistently negative, reflecting inadequate cash generation relative to net losses. Free cash flow has not shown significant improvement, suggesting ongoing cash flow challenges.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.93M	0.00	0.00	0.00	0.00	0.00
	Gross Profit
1.59M	0.00	-399.00K	-1.01M	-345.00K	0.00
	EBIT
-88.43M	-89.68M	-88.87M	-68.88M	-42.41M	-6.29M
	EBITDA
-87.97M	-89.68M	-88.47M	-67.30M	-42.94M	-28.55M
	Net Income Common Stockholders
-82.60M	-84.26M	-82.64M	-67.73M	-43.25M	-28.55M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
24.15M	97.80M	117.94M	186.60M	91.42M	24.15M
	Total Assets
25.30M	117.69M	140.86M	200.39M	102.44M	25.30M
	Total Debt
303.00K	12.95M	13.85M	176.00K	937.00K	303.00
	Net Debt
-23.85M	-26.07M	-38.14M	-186.43M	-90.48M	-24.15M
	Total Liabilities
6.54M	46.06M	24.61M	11.31M	171.88M	53.58M
	Stockholders Equity
18.75M	71.64M	116.25M	189.08M	-69.44M	-28.28M
Cash Flow		Free Cash Flow
-48.61M	-51.23M	-71.04M	-66.07M	-39.55M	-5.68M
	Operating Cash Flow
-48.59M	-51.22M	-70.36M	-65.15M	-39.35M	-5.18M
	Investing Cash Flow
11.59M	8.76M	-65.14M	-921.00K	-204.00K	-500.00K
	Financing Cash Flow
25.11M	29.49M	888.00K	161.25M	107.75M	29.83M

Vigil Neuroscience Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VIGL, the sentiment is Negative. The current price of 1.8 is below the 20-day moving average (MA) of 2.11, below the 50-day MA of 2.33, and below the 200-day MA of 3.08, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 38.35 is Neutral, neither overbought nor oversold. The STOCH value of 19.17 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VIGL.

Vigil Neuroscience Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BIIB	67 Neutral	$20.37B	12.74	10.36%	―	-1.60%	39.71%
ALNY	59 Neutral	$36.55B	―	-414.62%	―	22.97%	38.54%
IONS	49 Neutral	$5.01B	―	-93.03%	―	-10.48%	-18.79%
Sector *	49 Neutral	$6.88B	0.82	-52.97%	2.48%	20.92%	1.17%
SAGE	48 Neutral	$528.74M	―	-63.37%	―	-52.30%	27.13%
DNLI	41 Neutral	$2.01B	―	-37.40%	―	-100.00%	-144.79%
VIGL	32 Underperform	$84.01M	―	-89.69%	―	―	3.01%

Vigil Neuroscience Inc Corporate Events

Vigil Neuroscience Announces Positive Phase 1 Trial Results

On January 23, 2025, Vigil Neuroscience announced positive results from its completed Phase 1 clinical trial of VG-3927, a small molecule TREM2 agonist, aimed at treating Alzheimer’s disease. The trial demonstrated a favorable safety and tolerability profile, along with significant pharmacokinetic and pharmacodynamic markers, supporting the drug’s advancement to a Phase 2 trial scheduled for the third quarter of 2025. This development positions VG-3927 as a promising once-daily oral therapy that could offer a more convenient treatment option for Alzheimer’s patients, potentially addressing disease progression beyond targeting amyloid plaques.